Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas

A phase 1 study of the PI3K  inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

(2014) B. S. Kahl et al.   BLOOD

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells

(2014) Jiao Ma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma

(2014) James S. Blachly et al.   BRITISH JOURNAL OF HAEMATOLOGY

New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?

(2014) M. Dreyling et al.   CLINICAL CANCER RESEARCH

Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

(2014) M. V. Ramana Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models

(2014) X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

(2014) D. Chiron et al.   Cancer Discovery

Class IA Phosphatidylinositol 3-Kinase Inhibition Inhibits Cell Growth and Proliferation in Mantle Cell Lymphoma

(2013) Yoko Tabe et al.   ACTA HAEMATOLOGICA

Putative Roles for PI3K α and δ Isoforms in Refractory Mantle Cell Lymphoma

(2013) Katti A. Jessen et al.   ACTA HAEMATOLOGICA

P110 -mediated constitutive PI3K signaling limits the efficacy of p110 -selective inhibition in mantle cell lymphoma, particularly with multiple relapse

(2013) S. Iyengar et al.   BLOOD

Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1

(2013) David Chiron et al.   CELL CYCLE

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

(2013) Rami Rahal et al.   NATURE MEDICINE

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy

(2012) Hua Lv et al.   AAPS Journal

Taking it up a notch in MCL

(2012) S. Parekh   BLOOD

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Akt, FoxO and regulation of apoptosis

(2011) Xinbo Zhang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

New molecular targets in mantle cell lymphoma

(2011) Samir Parekh et al.   SEMINARS IN CANCER BIOLOGY

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The PI3K Isoforms p110  and p110  Are Essential for Pre-B Cell Receptor Signaling and B Cell Development

(2010) F. Ramadani et al.   Science Signaling

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

(2008) J. Dal Col et al.   BLOOD